94O - Lung adenocarcinoma with RET fusion: early experience with diagnosis and targeted therapy

Date 27 March 2014
Event ELCC 2014
Session Proffered Papers 1 - Advanced disease with tageted agents
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Translational Research
Presenter Oliver Gautschi
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors O. Gautschi1, G. Pall2, A. Schultheis3, F. Aebersold Keller4, M. Gardizi3, J. Heuckmann5, S. Merkelbach-Bruse3, J. Diebold4, J. Wolf6, L. Heukamp3
  • 1Klinik Für Onkologie, Luzerner Kantonsspital, 6004 - Luzern/CH
  • 2Innere Medizin, Universitätskliniken Innsbruck, 6020 - Innsbruck/AT
  • 3Institut Für Pathologie, Universitätsklinikum Köln, 50924 - Köln/DE
  • 4Institut Für Pathologie, Luzerner Kantonsspital, 6000 - Luzern/CH
  • 5Backfield Ag, Blackfield AG, 51105 - Köln/DE
  • 6Innere Medizin, Universitätsklinikum Köln, 50937 - Köln/DE

 

Abstract

Lung adenocarcinoma with RET fusion is a new diagnostic entity with potential clinical implications. Experience with diagnosis and targeted therapy is limited.